G1 Therapeutics Analysis
GTHXDelisted Stock | USD 7.15 0.00 0.00% |
G1 Therapeutics is overvalued with Real Value of 5.02 and Hype Value of 7.14. The main objective of G1 Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what G1 Therapeutics is worth, separate from its market price. There are two main types of G1 Therapeutics' stock analysis: fundamental analysis and technical analysis.
The G1 Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. G1 Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. GTHX Stock trading window is adjusted to America/New York timezone.
GTHX |
GTHX Stock Analysis Notes
About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.86. G1 Therapeutics had not issued any dividends in recent years. G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people. To learn more about G1 Therapeutics call John Bailey at 919 213 9835 or check out https://www.g1therapeutics.com.G1 Therapeutics Investment Alerts
G1 Therapeutics is not yet fully synchronised with the market data | |
G1 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
GTHX is showing solid risk-adjusted performance over 90 days | |
The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M. | |
G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
G1 Therapeutics Upcoming and Recent Events
Earnings reports are used by G1 Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
6th of March 2024 Upcoming Quarterly Report | View | |
1st of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
G1 Therapeutics Thematic Classifications
In addition to having G1 Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer FightersPublic companies from health care and pharmaceutical sectors that are focused on fighting cancer |
GTHX Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 377.22 M.GTHX Profitablity
The company has Profit Margin (PM) of (0.77) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.21) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.21.G1 Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific G1 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on G1 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases G1 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
John Bailey over three months ago Disposition of 2592 shares by John Bailey of G1 Therapeutics at 3.1189 subject to Rule 16b-3 | ||
John Bailey over three months ago Disposition of 7662 shares by John Bailey of G1 Therapeutics at 2.5077 subject to Rule 16b-3 | ||
John Bailey over six months ago Disposition of 37258 shares by John Bailey of G1 Therapeutics at 4.7888 subject to Rule 16b-3 | ||
Umstead John V. over six months ago Disposition of 6000 shares by Umstead John V. of G1 Therapeutics at 5.73 subject to Rule 16b-3 | ||
Umstead John W. V over six months ago Disposition of 6547 shares by Umstead John W. V of G1 Therapeutics at 3.0169 subject to Rule 16b-3 | ||
Mark Velleca over a year ago Exercise or conversion by Mark Velleca of 57286 shares of G1 Therapeutics subject to Rule 16b-3 | ||
Mark Velleca over a year ago Exercise or conversion by Mark Velleca of 10000 shares of G1 Therapeutics subject to Rule 16b-3 |
G1 Therapeutics Outstanding Bonds
G1 Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. G1 Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GTHX bonds can be classified according to their maturity, which is the date when G1 Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 4875 Corp BondUS55336VAG59 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
G1 Therapeutics Predictive Daily Indicators
G1 Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of G1 Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About GTHX Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how G1 Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GTHX shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as G1 Therapeutics. By using and applying GTHX Stock analysis, traders can create a robust methodology for identifying GTHX entry and exit points for their positions.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding G1 Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Transaction History View history of all your transactions and understand their impact on performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |